key: cord-0294613-y4nncqfp authors: Mancuso, M.; Eikenberry, S.; Gumel, A. title: Will Vaccine-derived Protective Immunity Curtail COVID-19 Variants in the US? date: 2021-07-05 journal: nan DOI: 10.1101/2021.06.30.21259782 sha: 74f31f63a8bacb8744b32d682771a5e0862af320 doc_id: 294613 cord_uid: y4nncqfp Multiple effective vaccines are currently being deployed to combat the COVID-19 pandemic (caused by SARS-COV-2), and are viewed as the major factor in marked reductions in disease burden in regions around the world with moderate to high coverage of these vaccines. The effectiveness of COVID-19 vaccination programs is, however, significantly threatened by the emergence of new SARS-COV-2 variants that, in addition to being more transmissible and potentially more virulent than the wild (resident) strain, may at least partially evade existing vaccines. A new two-strain (one resident, the other wild) and two-group (vaccinated or otherwise) mechanistic mathematical model is designed and used to assess the impact of the vaccine-induced cross-protective efficacy on the spread the COVID-19 pandemic in the United States. Analysis of the model, which is fitted using COVID-19 mortality data for the US, shows that vaccine-induced herd immunity can be achieved if 61% of the American population is fully vaccinated with the Pfizer or Moderna vaccines. Parameter sensitivity analysis suggests three main factors that significantly affect the COVID-19 burden in the US, namely (a) daily vaccination rate, (b) the level of cross-protection the vaccines offer against the variant, and (c) the relative infectiousness of the dominant variant relative to the wild strain. This study further suggests that a new variant can cause a significant disease surge in the US if (i) the vaccine coverage against the wild strain is low (roughly < 50%), (ii) the variant is much more transmissible (e.g., twice more transmissible) than the wild-type strain, or (iii) the level of cross-protection offered by the vaccine is relatively low (e.g., less than 70%). A new variant will not cause such surge in the US if it is only moderately more transmissible (e.g., 1:56 more transmissible) than the wild strain, at least 66% of the population of the US is fully vaccinated, and the three vaccines being deployed in the US (Pfizer, Moderna, and Johnson & Johnson) offer a moderate level of cross-protection against the variant. Since its emergence late in December 2019, the novel coronavirus pandemic , caused by the RNA virus SARS-COV-2, has spread to every corner of the world. While other coronavirus pandemics have emerged in recent decades, (including the 2002-2004 severe acute respiratory syndrome (SARS-CoV-1) and the 2012-present middle eastern respiratory syndrome (MERS-CoV) pandemics (50)), COVID-19 represents the greatest global public health challenge since the 1918-1919 influenza pandemic. As of June 18, 2021, there have been over 176 million confirmed COVID-19 cases and over 3.8 million deaths worldwide, with the US the most affected county (with over 33 million confirmed cases and now over 600,000 COVID-19 deaths), although cases and deaths may be dramatically under-counted in some communities or jurisdictions (17) . The most common symptoms of COVID-19 disease include dry cough, shortness of breath, fever, fatigue, muscle aches, and loss of taste or smell. Symptoms develop roughly 2-14 days after contacting the SARS-CoV-2 virus, likely via respiratory droplets or aerosols, and typically last for up to two weeks, although a minority experience "long COVID-19," when symptoms endure for several weeks or months, and interfere with day-to-day life (13) . The severity of symptoms varies widely from wholly asymptomatic disease to severe multi-organ system failure and death. Risk of a poor outcome increases with comorbidities, such as immunocompromised status, heart or lung disease, diabetes, etc., while the mortality rate increases exponentially with age. Transmission to susceptible individuals peaks early in the natural history of the disease, with infected individuals infectious several days before the onset of symptoms (pre-symptomatic stage); those who never develop symptoms may also still pass the disease as asymptomatic carriers (14) . ORCID Click here to view linked References 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 Will Vaccine-derived Immunity Curtail COVID- 19? thousand strains of the SARS-CoV-2 virus each week, this still amounts to less than 1% of total infections reported (12) . Recent studies regarding the cross-protective immunity of existing vaccines on the SARS-CoV-2 VOCs have shown varying results (52; 70; 30; 71) . Some studies evaluating the cross-efficacy of the Pfizer-BioNtech vaccine on the B.1.1.7 and B.1.351 variants showed no significant differences of antibody neutralization when two doses of the vaccine were delivered 18-28 days apart (52; 71) . However, for those who acquired immunity through infection recovery (convalescent immunity) or only received a single dose of the vaccine, less neutralizing antibodies were produced, particularly for the B.1.351 variant (52; 4) . Another study compared the cross-efficacy of the B.1.1.7 and B.1.351 variants when two doses of the Moderna vaccine was administered 28 days apart (70) , which showed reduction in antibody neutralization for the B.1.351 strain, but not the B.1.1.7 strain. Further research is needed to validate and confirm these initial reports. Despite the uncertainty regarding the level of cross-efficacy that current EUA vaccines provide against VOCs, some researchers showed that there is, at least, some degree of cross-protection (58; 12) . However, it is of major public health interest to understand how new variants can, in principle, impact the community, and if the current vaccination program will be enough to eliminate the pandemic in the United States, under a plausible range of scenarios with respect to variant transmissibility and cross-protection. During the earliest days of the COVID-19 pandemic, before extensive experimental or case data was available, mathematical modeling was a useful tool to gauge the severity and potential impact that the disease would have on the community (35; 37; 43; 54; 55; 27; 72; 56; 26; 19; 40; 24; 39; 49; 32; 33) . With the increased availability and administration of the Pfizer, Moderna, and Johnson & Johnson vaccines in the US, as well as uncertainties surrounding the recently emerged SARS-CoV-2 variants, mathematical modeling can be a very useful tool to estimate the extent cross-protective immunity from vaccines protect the community from the emerging COVID-19 variants. The current study uses a novel mathematical model to assess the impact of vaccination and vaccine-induced cross-protection against the B.1.1.7 and other SARS-CoV-2 variants circulating in the US as of June 2021. The two-strain and two-group model, which takes the form of a deterministic system of nonlinear differential equations, is formulated in Section 2.1. The model is fitted using COVID-19 mortality data, and a key unknown parameter of the model was estimated from the fitting. Further, basic qualitative features of the model, including the derivation of vaccine-derived herd immunity threshold for the US and parameter sensitivity analysis, are discussed in Section 3.1. Numerical simulations are presented in Section 3.4. In this section, the new two-strain, two-group mechanistic model for the transmission dynamics of two SARS-CoV-2 strains (the wild-type and variant strains) in the presence of vaccination, is formulated. The total population of individuals in the community at time , denoted by ( ), is stratified into two groups based on vaccination status, namely the total unvaccinated group, denoted by ( ) and the total vaccinated group denoted by ( ), so that ( ) = ( ) + ( ). The total unvaccinated population ( ( )) is further stratified into the mutually-exclusive compartments of individuals that are unvaccinated susceptible ( ), latent or "exposed" ( ), pre-symptomatically infectious ( ), symptomatically infectious ( ), asymptomatically infectious ( ), hospitalized ( ), and recovered ( ), with = 1, 2 (represents the SARS-CoV-2 strain), so that Similarly, the total vaccinated population ( ( )) is sub-divided into the sub-populations of individuals that are vaccinated susceptible ( ( )), exposed ( ), pre-symptomatically infectious ( ), symptomatically infectious ( ), asymptomatically infectious ( ), hospitalized ( ), and recovered ( ), with = 1, 2. Thus, 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 Vaccinated individuals are assumed to have received the full required doses (i.e., they are fully vaccinated). The equations for the rate of change of the aforementioned state variables of the two-strain, two-group vaccination model for COVID-19 transmission dynamics and control in the US are given by the deterministic system of nonlinear differential equations in Equation (A-8) of Appendix A. The flow diagram of the model is depicted in Figure 1 , and the state variables and parameters of the model are described in Tables A.7 and A.8, respectively. In the formulation of the model (A-8), we assume a setting where two strains of SARS-CoV-2 are co-circulating in the population: strain 1, the wild-type (original) strain that is assumed to be the predominant strain circulating the US throughout 2020 (42) and strain 2, a new dominant, variant strain assumed to be circulating in the US since the end of 2020 (18)). For mathematical tractability and convenience, we assume that susceptible individuals can be infected with either of the two strains, but not with both. Further, we have no real evidence for co-infection of multiple SARS-CoV-2 strains at the current moment. The three EUA vaccines in the US (i.e., the Pfizer, Moderna, and Johnson & Johnson vaccines) target the wild-type strain with efficacy , and are assumed to induce cross-protective efficacy ( ) against the dominant variant (strain 2) (52; 71; 30; 70) . Vaccination is offered to all eligible unvaccinated individuals, but for simplicity, the model does not consider vaccination of currently infected individuals (symptomatic or asymptomatic). In other words, the model only considers vaccinating those who are wholly-susceptible and those who recovered from the disease prior to being vaccinated. Although currently infectious individuals may be getting vaccinated, they comprise of extremely small fraction of the overall population at any given time, and are not included (for simplicity). Some of the other main assumptions made in the formulation of the model (A-8) include the following: (i) Homogeneous mixing: the population is well-mixed, such that every member of the community is equally likely to mix with every other member of the community. Further, the waiting times in each epidemiological compartment are exponentially distributed (36) . (ii) Because of the inherent age structure in the COVID-19 vaccine administration (where, in the context of the Pfizer vaccine, for instance, only people at age 12 or older are vaccinated (60)), we include demographic (birth and death) parameters to account for the inflow of new susceptible individuals that are eligible for vaccination. (iii) Vaccination is only offered to wholly-susceptible individuals or those who naturally recovered from COVID-19 infection (but not for currently-infected individuals). (iv) Vaccinated individuals are assumed to have received the full recommended dosage (two doses for Pfizer or Moderna vaccine, one dose for the Johnson & Johnson vaccine), and that the vaccine administered was stored at the appropriate temperatures, and that enough time has elapsed for the body to develop immunity. (v) The vaccines are imperfect against infection (i.e, breakthrough infection can occur) (60; 59; 61). The vaccines offer strong therapeutic benefits, vis a vis reducing severe disease, hospitalization, and death (60; 59; 61). (vi) Vaccine-derived and natural immunity may wane over time in individuals, in which they revert to the whollysusceptible class. In this section, the model (A-8) is fitted using the cumulative mortality data from Johns Hopkins' Center for Systems Science & Engineering (from January 22, 2020 to March 6, 2021) (17) and daily vaccination data from Bloomberg (from December 21, 2020 to March 6, 2021) (8) for the US. Fitting is used to estimate the contact rate parameter for the wild-type strain (strain 1), 1 , during each wave of the COVID-19 pandemic in the US (17; 8) . The fitting is done in the absence of vaccination for the period from January 22, 2020 to January 21, 2021, and including vaccination for January 22, 2021 to March 6, 2021. We use a MATLAB routine to minimize the sum of squared differences between each observed cumulative mortality data point and the corresponding mortality point obtained from the model (A-8). COVID-19 mortality data, rather than case data, is used to fit the model since it is more reliable (the latter underestimates the true number of cases owing to the inability to track asymptomatic and pre-symptomatic cases, resulting from the absence of random wide-scale testing across the US) (14) . Will Vaccine-derived Immunity Curtail COVID-19? The first case of the B.1.1.7 variant was documented in the US on December 29, 2020 (18), although the variant was likely introduced to the US prior to detection. For the actual fitting, we introduce 1,000 cases of a variant strain (i.e., 2 (0) = 1, 000) on December 29, 2020 to estimate variant infections present prior to confirmation of its US detection. Further, vaccination is introduced in the model (A-8) on January 21, 2021. Since our model does not explicitly consider the two-dose vaccine structure or account for any delay from inoculation to (partial) immunity, we introduce a delay from actual to modeled vaccination by constructing an inferred second dose time-series. That is, the available data only gives total doses delivered and does not disaggregate between first and second doses. Therefore, we assume that during the first 30 days of vaccine reporting, all administered doses are first doses. After 30 days, all first doses result in a second dose, and any remaining doses for that day are considered first doses. An inferred second dose time series can thus be constructed iteratively. Second doses were roughly 35% of the total doses administered each day following the first four weeks of vaccination (8) . Furthermore, the following expression was used to determine the time-dependent vaccination rate, ( ): This expression allows for the realistic possibility that individuals who have recovered from infection (and may have naturally-acquired immunity against future infection) will be vaccinated along with susceptible individuals. Thus, a proportion of the vaccination doses administered each day are delivered to wholly-susceptible individuals who have not developed prior COVID-19 immunity. The result of the data fitting of the model (A-8), using the fixed parameters in Table A .9, is depicted in Figure 2 . Will Vaccine-derived Immunity Curtail COVID-19? Table 1 , illustrating the daily mortality generated from the model, in comparison to the observed daily mortality data for the US. For both panel, initial conditions used were (0) = 336 million, 1 (0) = 10 and all other state variables set at zero. The purple vertical line shows the time that 1,000 cases of the variant strain (strain 2) was introduced in the population (December 29, 2020), and assumed to be 1.56 times as infectious as strain 1 (20) . The brown vertical line shows the time at which vaccination was introduced into the model (January 22, 2021) using data from (8) . The contact rate, 1 , varies throughout the course of the pandemic due to implementation and compliance of nonpharmaceutical interventions (NPIs) and vaccination. Table 1 shows the values of the contact rate for the wild-type strain (strain 1), 1 , for each period of the pandemic. The first wave of the COVID-19 pandemic (January 22, 2020 to April 1, 2020) was the period with the highest contact rate, and occurred prior to most wide-scale NPI implementation (particularly the CDC's recommendation of face mask usage). The lockdown period (April 2, 2020 to June 15, 2020) was the period when numerous US states implemented stay-at-home policies, and was shown to have a lower contact rate. The second wave, which occurred during the early to mid summer of 2020 (June 16, 2020 to July 20, 2020) and was period when many states stay-at-home orders expired and businesses started returning to operation. This resulted in a higher contact rate, which in turn lead to more observed COVID-19 mortality. Many states began tightening restrictions on businesses again after seeing the rise in cases and deaths, which resulted in the post-second wave period (July 21, 2020 to September 18, 2020) having a decreased contact rate. As states lifted business restrictions and other COVID-19 related NPIs in mid-September, 2020 (66) , and many Americans traveled for the holidays, a large third wave of the pandemic was observed for September 19, 2020 to January 6, 2021, that had a similar contact rate as the second wave. As vaccination distribution commenced towards the final weeks of 2020, the contact rate once again decreased to a level similar to the post-second wave contact rate. We note that during the second and third waves, most US states still maintained a baseline level of NPI implementation and compliance (e.g., social distancing polices, face 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 Will Vaccine-derived Immunity Curtail COVID-19? mask mandates). Thus, the contact rates for the second and third waves were not as high as the initial pandemic wave. In this section, the reproduction number of the model (A-8) is computed for the special case where the vaccination rate, ( ), is treated as constant. That is, We consider the autonomous version of the model with ( ) = , a constant. The autonomous version of the model (A-8) has a unique disease-free equilibrium (DFE) given by and all other components of 0 are zero. The next generation operator method (64; 21) can be used to analyze the local asymptotic stability of the DFE ( 0 ). Noting that * = * + * , and using the notation in (64) , it follows that the non-negative matrix ( ) of new infection terms, and the matrix ( ) of new transition terms, are, respectively, given by: where the matrices F 1 , F 2 , M 1 and M 2 are given in Appendix B, and 0 10×10 denotes the zero matrix of order 10. It follows that the vaccination reproduction number of the autonomous version of the model (A-8), denoted by  , is given by (where denotes the spectral radius of the next generation matrix FM −1 ) where  [1] and  [2] (given in Appendix B) represent, respectively, the constituent reproduction numbers associated with the transmission of strains 1 and 2. The result below follows from Theorem 2 of (64). The DFE ( 0 ) of the autonomous version of the model (A-8) is locally-asymptotically stable if  < 1, and unstable if  > 1. The threshold quantity,  , measures the average number of new COVID-19 cases generated by a single infectious individual introduced into a population where a certain proportion is vaccinated. The epidemiological implication of Theorem 3.1 is that a small influx if COVID-19 cases will not generate an outbreak in the community if the vaccination reproduction number ( ) is brought to (and maintained at) a value less than unity. Herd immunity, which is a measure the fraction of susceptible individuals that need to be protected against infection in order to eliminate community transmission of an infectious disease, can be attained through two main ways: natural recovery from infection or from vaccination. However, the safest and fastest way to achieve herd immunity is through vaccination (6; 5) . Furthermore, at least 15% of the U.S. population currently cannot be vaccinated due to age restrictions (57 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 as well as for other reasons, may be unable or unwilling to be vaccinated against COVID-19. Thus, it is critical to know what minimum proportion of the susceptible US population need to be vaccinated to achieve herd immunity (so that the pandemic can be effectively controlled). In this section, we derive the expression for achieving herd immunity against COVID-19 in the US based on widespread vaccination against the wild-type SARS-CoV-2 strain (i.e., strain 1). In the absence of vaccination and other public health interventions (e.g., social-distancing, mask wearing, etc), the vaccination reproduction number ( ) reduces to the basic reproduction number (denoted by  0 ) given below: where  1 and  1 are the constituent basic reproduction numbers for the wild-type (strain 1) and the variant (strain 2) SARS-CoV-2 strains, respectively, given by (where , with = 1, 2, ⋯ , 20 are given in Appendix B):  1 = 1 [ 1 5 7 9 1 + 7 9 1 1 + 1 5 9 (1 − ) 1 . For the case when all individuals in the population are vaccinated, the constituent reproduction numbers for the wildtype (strain 1) and variant (strain 2) SARS-CoV-2 strains become: and  2 = 2 (1 − ) ( 5 + 6 + 7 + 8 ) 12 14 16 18 20 , where expressions for , = 1, 2, ...8 are also given in Appendix B. Hence, for the case where all individuals in the population are vaccinated, the expression for the vaccination reproduction number of the model is given by: It follows that the vaccination reproduction numbers of wild-type (strain 1,  [1] ) and variant (strain 2,  [2] ) can be re-written in terms of their basic reproduction numbers  1 and  2 , and reproduction numbers when the entire population is vaccinated, as below: where = * * is the proportion of susceptible individuals in the community who have been vaccinated (at steadystate). The herd immunity threshold is computed by setting [1] = 1 and solving for (noting that it is necessary to ensure, in this computation, that 0 <  1 ≤ 1 <  1 ). Doing so gives: 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 Will Vaccine-derived Immunity Curtail COVID-19? Table A .9, with the contact rate set at 1 = 0.24. Using the fixed parameters in Table . The model (A-8) contains numerous parameters, and uncertainties arise in the estimated values of some of the parameters (e.g., those related to vaccination and dynamics of variants) used in the numerical simulations. In this section, sensitivity analysis is carried out, using Latin Hypercube Sampling (LHS) and Partial Rank Correlation Coefficients (PRCC) (45; 9; 46), to determine the parameters that have the highest influence on the value of the chosen response function. Sensitivity analysis measures the extent that a response function changes with respect to variations in the input variables. For this study, the vaccination reproduction number for the variant strain ( [2] ) was used as the response function. One thousand bootstrap sample iterations were used for the LHS, and PRCC determined the correlation each individual parameter has on the response function ( [2] ). The baseline value of the contact rate, 2 was chosen as 0.24, with additional baseline values for fixed parameters from Table A.9. The PRCC values generated for the parameters in the expression of the response function,  [2] , are tabulated in Table 2 . The contact rate of the variant strain ( 2 ), the fraction of non-vaccinated and vaccinated individuals who experience symptomatic infection from the variant strain ( , ), and the modification parameter ( 2 ) accounting for relative infectiousness of non-vaccinated asymptomatic individuals infected with the variant strain compared to non-vaccinated asymptomatic individuals infected with the wild-type strain have the greatest PRCC magnitude. That is, 2 , , , and 2 most affect the vaccination reproduction number of the variant strain ( [2] ), and, thus, the dynamics of the model (A-8). 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 Will Vaccine-derived Immunity Curtail COVID-19? Table 2 PRCC values for the parameters of the model (A-8), using the vaccination reproduction number of the variant strain,  [2] . Parameter values that most affect the dynamics of the model are highlighted in bold font. The model (A-8) is now simulated using the fixed parameters in Table A Due to inconclusive data surrounding the length of vaccine and naturally-acquired immunity, we assume for the period of simulation that previously infected individuals remain in their respective recovered classes. This assumption is consistent with other COVID-19 modeling studies (32; 33; 49; 48; 39; 24) . Thus, results using administration of the Johnson & Johnson vaccine are not shown, since the assumption that individuals will not become re-infected during the simulation period results in an overall lower COVID-19 compared to administering the Pfizer/Moderna vaccines. In other words, under administration of the less efficacious Johnson & Johnson vaccine ( = 0.67), more individuals will become infected with the less deadly wild-type strain rather than the more deadly variant strain. Furthermore, since less than 8% of fully-vaccinated individuals in the US have received the Johnson & Johnson vaccine (11) , simulations under Pfizer/Moderna vaccine administration can better estimate the future course of the pandemic. Data from (42) suggests that the B.1.1.7. variant is 1.56 times more transmissible (i.e., 1.56 times more infectious) than the wild-type strain in the US. Here, we simulate the dynamics of the two strains under this assumption, for various levels of full-vaccination coverage (50%, 66%, 75%) and cross-protective vaccination efficacy ( = 0, 0.25, 0.5, 0.7) offered by the Pfizer/Moderna vaccines. Cumulative COVID-19 related deaths and cases for Scenario 1 are tabulated in Table 3 , and values and occurrence of the peak daily COVID-19 related deaths and new infections are included in Table 4 . The absolute worst-case-scenario for the population would be if the vaccines do not offer any cross-protection (i.e, if = 0). Fortunately, the three EUA vaccines currently used in the US do offer a significant level cross-protective efficacy against existing variants (58; 12) . However, it is helpful to quantify how much morbidity and mortality burden from the variant strain could be averted through cross-protection. 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 Will Vaccine-derived Immunity Curtail COVID-19? and deaths would be caused by the variant strain. The peak daily burden would be experienced during mid September 2021, with over 2 million new cases per day. If 50% of the US population became fully-vaccinated, then as much as 192,000 to 918,000 lives can be saved under 25% to 70% cross-protective vaccination efficacy. If vaccination coverage is increased to 75%, then 3 to 14.8 million deaths can be averted. At a moderately-high level of cross-protective efficacy ( = 0.7), then even vaccination coverage levels as low as 66% can avoid another pandemic wave. Figure 4 shows the simulations of Scenario 1 when 75% of the US population is fully vaccinated with the Pfizer/Moderna vaccines. If we assume now that the variant is, instead, twice as transmissible as the wild-type strain in the US, the worst-casescenario ( = 0) would cause an additional 214,000 cumulative deaths and 17.6 million cases than the worst case from Scenario 1. The peak of daily cases and deaths would shift 9 weeks earlier to late July 2021 and exceed 3.76 million new cases a day. If 50% of the US population is fully vaccinated, 23.5 to 35.5 million more cases and 300,000 to 432,000 more deaths may occur when compared to the same vaccination coverage under Scenario 1. An additional 17.6 to 44.1 million cumulative cases and 214,000 to 537,000 cumulative deaths will occur under 75% vaccination coverage when compared to Scenario 1. With a more infectious variant strain, even high levels of vaccination coverage (75%) and cross-protective vaccination efficacy ( = 0.7) will result in a future pandemic wave. Figure 5 shows the simulations of Scenario 2 when 75% of the US population is fully vaccinated with the Pfizer/Moderna vaccines. Cumulative COVID-19 related deaths and cases for Scenario 2 are tabulated in Table 5 , and values and occurrence of the peak daily COVID-19 related deaths and new infections are included in Table 6 . Page 11 of 25 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 Will Vaccine-derived Immunity Curtail COVID-19? Since the emergence of COVID-19 in Wuhan, China late 2019, the COVID-19 pandemic has ravaged the world by infecting every country and altered life as we know it. Fortunately, scientists and researchers have swiftly developed several vaccines to combat the virus using mRNA (Pfizer and Moderna) and adenovirus (Johnson & Johnson) technology. Over 2.23 billion shots have been administered worldwide as of June 18, 2021 and over 43% of the US population is fully vaccinated (7; 11). However, recent variants of SARS-CoV-2 have emerged and become a public health concern, particularly: the B.1.1.7 variant first discovered in the UK, the B.1.351 variant initially found in South Africa, the P.1 variant that originated from Brazil, and the B.1.617.2 variant from India have infected numerous countries, including the US. Current data and studies show strong evidence that these variants are more easily transmissible and have higher rates of hospitalization and disease-induced death. The greatest concern of the variants is the inconclusive cross-protective efficacy from the current COVID- 19 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 Will Vaccine-derived Immunity Curtail COVID-19? 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 Will Vaccine-derived Immunity Curtail COVID-19? Wide-scale vaccination is essential to eliminating the pandemic and reducing the overall COVID-19 burden. The vaccination coverage level, cross-protective vaccination efficacy against variant strains, and the relative infectiousness of the variant strain when compared to the wild-type strain all greatly influence the dynamics of the model (A-8) . Both cross-protective vaccination efficacy against the variant and vaccination coverage shift the peak of daily cases and deaths forward in time with increasing levels. The peak of daily deaths is expected to occur approximately 10 to 16 days after the peak of daily infections occurs. No data is currently available about if, or how much infectiousness is reduced by vaccinated individuals. Therefore, this study assumes that vaccinated individuals, when infected, are equally likely to transmit infection as non-vaccinated individuals ( = = 1). This study also assumes that exclusive deployment of the Pfizer or Moderna vaccines in the simulations. 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 that individuals who recovered from the wild-type strain ( 1 class) could be directly infected by the variant strain without losing developed immunity from the wild-type strain. This would alter the vaccination reproduction number and basic reproduction number expressions of the model (A-8) . The B.1.1.7 is currently the most dominant variant circulating in the US population (12; 16) , and estimated to be 56% more infectious than the wild-type strain (20) . The numerical simulations showed that if a moderate level of vaccination coverage (≥ 66% of the US population) and moderately-high level of cross-protective vaccination efficacy ( ≥ 0.7) is attained, then a surge of variant-induced COVID-19 infections and mortality will not occur (under the assumption that both vaccine and naturally-acquired immunity lasts at least two years). One study showed that crossprotective efficacy is as high as 93% against the B.1.1.7 variant when two doses of the Pfizer vaccine are administered, but drops to 33% when only one dose is received (31) . If the variant is much more transmissible than the wildtype strain, then even at moderately high levels of cross-protective efficacy ( = 0.7) and vaccine coverage (75% of the US population), the U.S. could still experience a severe wave of COVID-19 cases caused by variant strains that will be detrimental to the community. Numerical simulations show that if the US experiences another wave of infections, the peak daily COVID-19 related deaths and new cases are almost exclusively from the variant strain. This could result in another period of lockdown and exacerbate morbidity and mortality from the virus. Despite many states relieving COVID-19 related restrictions and face mask mandates now that vaccination has become more widely available (22; 3) , it imperative that we continue to follow non-pharmaceutical intervention (NPI) protocol. Further, the risk of the B. 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 Will Vaccine-derived Immunity Curtail COVID-19? The two-strain, two-group vaccination model for the COVID-19 transmission dynamics and control in the US is given by the following deterministic system of nonlinear differential equations: The parameter Π is the recruitment rate (via birth or immigration) of individuals into the population. Individuals are vaccinated at a time-dependent rate ( ). The vaccine is assumed to produce protective efficacy 0 < < 1 against 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 Will Vaccine-derived Immunity Curtail COVID-19? In (A-9) and (A-10), (with = 1, 2) is the effective contact rate for strain , ( ), ( ), and ( ) are, respectively, the modification parameters accounting for the assumed increase or reduction of contact rates of unvaccinated (vaccinated) pre-symptomatic, asymptomatic, and hospitalized individuals with strain , compared to symptomatic infectious individuals with strain . The modification parameter 0 ≤ ≤ 1 represents the assumed reduced infectiousness of individuals vaccinated against strain 1 (in comparison to unvaccinated infectious individuals with strain 1), while (0 ≤ ≤ 1) accounts for the assumed reduced infectiousness of strain 2 induced by the crossprotective of vaccination against strain 1. Unvaccinated (vaccinated) individuals in the exposed classes (strain 1 or strain 2) progress to their respective strain's pre-symptomatic class at rate ( ) where = {1, 2} indicates the strain of infection. Non-vaccinated (vaccinated) individuals transition out of the pre-symptomatic classes at rate ( ). For strain 1, fraction 0 < ( ) < 1 of individuals develop symptoms while (1 − ) ((1 − )) individuals remain asymptomatic infectious. The fraction of unvaccinated (vaccinated) individuals infected with strain 2 who develop symptoms is 0 < ( ) < 1. Non-vaccinated (vaccinated) symptomatic infectious individuals recover at rate ( ), become hospitalized at rate ( ), and die from diseased-induced death at rate ( ). Non-vaccinated (vaccinated) asymptomatic infectious individuals recover at rate ( ). Non-vaccinated (vaccinated) Hospitalized individuals recover at rate ( ) and die from disease-induced death rate ( ). Non-vaccinated (vaccinated) individuals lose their naturally-acquired disease-induced immunity at rate ( ). The state variables and parameters of the model are described in Tables A.7 and A.8, respectively. 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 The associated next generation matrices of the model (A-8) are given by: 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 Will Vaccine-derived Immunity Curtail COVID-19? 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 Will Vaccine-derived Immunity Curtail COVID-19? Using the approach in (34) , the vaccination reproduction numbers of the wild-type (strain 1) and variant (strain 2) SARS-CoV-2 strains are found from  respectively, where denotes the spectral radius. The expressions for  [1] and  [2] are given by: 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 Executive Order GA 14 Executive Order GA 29 Executive Order GA 34 Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants The concept of herd immunity and the design of community-based immunization programmes Vaccination and herd immunity to infectious diseases More Than 2.42 Billion Shots Given: Covid-19 Tracker Bloomberg Covid-19 Vaccine Tracker Open Data (2021) Sensitivity and Uncertainty Analysis of Complex Models of Disease Transmission: an HIV Model, as an Example The Advisory Committee on Immunization Practices' Updated Interim Recommendation for Allocation of COVID-19 Vaccine -United States COVID Data Tracker science/science-briefs/scientific-brief-emerging-variants.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov% 2Fcoronavirus%2F2019-ncov%2Fmore%2Fscience-and-research%2Fscientific-brief-emerging-variants Long-Term Effects Pandemic Planning Scenarios SARS-CoV-2 Variant Classifications and Definitions Variant Proportions COVID-19. Github repository Gov. Polis and State Public Health Officials Announce First Case of COVID Variant of COVID-19 in Colorado An agent-based model to evaluate the covid-19 transmission risks in facilities Estimated transmissible and severity of novel SARS-CoV-2 Variant of Concern 202012/01 in England On the definition and the computation of the basic reproduction ratio 0 in models for infectious diseases in heterogenous populations State of Arizona Executive Order 2021-06 State of Arizona Executive Order To mask or not to mask: Modeling the potential for face mask use by the general public to curtail the COVID-19 pandemic Theoretical Assessment of Public Health Impact of Imperfect Prophylactic HIV-1 Vaccines with Therapeutic Benefits Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand. London: Imperial College COVID-19 Response Team Using a real-world network to model localized covid-19 control strategies LIST: Arizona cities with face mask requirements Gatherings and Face Mask Order. Michigan Department of Health and Human Services Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies The Highly Contagious Delta Variant is On The Rise In The U.S. National Public Radio A primer on using mathematics to understand COVID-19 dynamics: Modeling, analysis, and simulations Mathematical assessment of the roles of vaccination and non-pharmaceutical interventions on COVID-19 dynamics: a multigroup modeling approach. medRxiv Existence of Multiple-Stable Equilibria for a Multi-Drug-Resistant Model of Mycobaceria Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts The mathematics of infectious diseases A stoachastic agent-based model of the sars-cov-2 epidemic in France NERVTAG note on B.1.1.7 severity for SAGE. New and Emerging Respiratory Virus threads Advisory Group Will an imperfect vaccine curtail the COVID-19 pandemic in the US? Infectious Disease Mancuso, Eikenberry & Gumel: Preprint submitted to Will Vaccine-derived Immunity Curtail COVID-19? Modelling Forecasting COVID-19 impact on hospital bed-days, ICU-days, ventilator-days, and deaths by US state in the next 4 months Florida Gov. Ron DeSantis issues statewide stay-at-home order Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus Early dynamics of transmission and control of covid-19: A mathematical modelling study. The Lancet Infectious Diseases COVID-19 vaccines: Get the facts A Comparison of Three Methods for Selecting Values of Input Variables in the Analysis of Output from a Computer Code Sensitivity and Uncertainty Analyses for a SARS Model with Time-Varying Inputs and Outputs MDH lab testing confirms nation's first known COVID-19 case associated with Brazil P.1 variant Mathematical assessment of the impact of non-pharmaceutical interventions on curtailing the 2019 novel Coronavirus Could masks curtail the post-lockdown resurgence of covid-19 in the US? COVID-19 MERS, & SARS. National Institute of Health Arizona governor issues 'stay-at-home' order; will take effect close of business Tuesday Vaccine-inuced immunity provides more robust heterotypic immunity than natural infection to emerging SARS-CoV-2 variants of concern South Carolina Public Health Officials Detect Nation's First Known Cases of the COVID-19 Variant Originally Detected in South Africa Understanding spatial heterogeneity of COVID-19 pandemic using shape analysis of growth rate curves Real-time monitoring the transmission potential of COVID-19 in Singapore A network-based explanation of why most covid-19 infection curves are linear National Demographic Analysis Tables: 2020 Coronavirus (COVID-19) Update: FDA Issues Policies to Guide Medical Product Developers Addressing Virus Variants United States Food and Drug Administration (2020) FDA Briefing Document Pfizer-BioNTech COVID-19 Vaccine FDA Issues Emergency Use Authorization for Third COVID-19 Vaccine FDA Takes Key Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for First COVID-19 Vaccine United States Food and Drug Administration Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data Florida governor extends order suspending COVID-19 related enforcement fines Executive Order No. 2020-42. State of Michigan Office of the Governor Executive Order No. 2020-60. State of Michigan Office of the Governor Executive Order No. 2020-110. State of Michigan Office of the Governor mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. biorxiv Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K, and N501Y variants by BNT162b2 vaccine-elicited sera A data-driven network model for the emerging covid-19 epidemics in Wuhan The authors declare no competing interests. Page 15 of 25 Page 25 of 25 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 ☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 5, 2021. ; https://doi.org/10.1101/2021.06.30.21259782 doi: medRxiv preprint